These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36845453)

  • 21. Real-Life Experience and Predictors of Visual Outcomes with Intravitreal Brolucizumab Switch for Treatment of Neovascular Age-Related Macular Degeneration.
    Cavalleri M; Tombolini B; Sacconi R; Gatta G; Valeri R; Bandello F; Querques G
    Ophthalmologica; 2023; 246(2):158-168. PubMed ID: 37040734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes.
    Edington M; Connolly J; Chong NV
    Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1217-1224. PubMed ID: 29134820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of efficacy of intravitreal ranibizumab between non-vitrectomized and vitrectomized eyes with diabetic macular edema.
    Chen YY; Chen PY; Chen FT; Chen YJ; Wang JK
    Int Ophthalmol; 2018 Feb; 38(1):293-299. PubMed ID: 28176171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brolucizumab for pre-treated patients with choroidal neovascularization and signs of tachyphylaxis to aflibercept and bevacizumab.
    Boltz A; Radunsky K; Weingessel B; Vécsei-Marlovits VP
    Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2561-2566. PubMed ID: 35348844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.
    Ogura Y; Jaffe GJ; Cheung CMG; Kokame GT; Iida T; Takahashi K; Lee WK; Chang AA; Monés J; D'Souza D; Weissgerber G; Gedif K; Koh A
    Br J Ophthalmol; 2022 Jul; 106(7):994-999. PubMed ID: 34301613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy.
    Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
    Sci Rep; 2021 Mar; 11(1):6759. PubMed ID: 33762600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration.
    Ota H; Takeuchi J; Nakano Y; Horiguchi E; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K
    Jpn J Ophthalmol; 2022 May; 66(3):278-284. PubMed ID: 35233693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravitreal Ranibizumab Versus Aflibercept for Diabetic Macular Edema in Vitrectomized Eyes: 12 Month Results.
    Türkseven Kumral E; Erçalık NY
    Semin Ophthalmol; 2021 Nov; 36(8):723-727. PubMed ID: 33760698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Real-life experiences with Brolucizumab in recalcitrant neovascular age-related macular degeneration].
    Book M; Ziegler M; Rothaus K; Faatz H; Gutfleisch M; Spital G; Lommatzsch A; Pauleikhoff D
    Ophthalmologe; 2022 Mar; 119(3):258-264. PubMed ID: 34351479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term outcomes of switching to brolucizumab in japanese patients with neovascular age-related macular degeneration.
    Kitajima Y; Maruyama-Inoue M; Ikeda S; Ito A; Inoue T; Yanagi Y; Kadonosono K
    Jpn J Ophthalmol; 2022 Nov; 66(6):511-517. PubMed ID: 36149566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Efficacy of Brolucizumab in the Treatment of Neovascular Age-Related Macular Degeneration: A Systematic Literature Review and Network Meta-Analysis.
    Finger RP; Dennis N; Freitas R; Quenéchdu A; Clemens A; Karcher H; Souied EH
    Adv Ther; 2022 Aug; 39(8):3425-3448. PubMed ID: 35678996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-Term Safety and Efficacy of Intravitreal Brolucizumab Injections for Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Real-World Study.
    Kim DJ; Jin KW; Han JM; Lee SH; Park YS; Lee JY; Lee EK; Lee JS; Kim ST; Shin MH; Lee CS; Jung HH; Jang JY; Kim M; Kim YH; Kim JH; Park KH; Park SJ; Joo K; Ji YS; Sagong M; Woo SJ
    Ophthalmologica; 2023; 246(3-4):192-202. PubMed ID: 36720210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term results for brolucizumab in treatment-naïve neovascular age-related macular degeneration: a Japanese multicenter study.
    Tanaka K; Koizumi H; Tamashiro T; Itagaki K; Nakayama M; Maruko I; Wakugawa S; Terao N; Onoe H; Wakatsuki Y; Kasai A; Ogasawara M; Shintake H; Sugano Y; Yamamoto A; Kataoka K; Hasegawa T; Izumi T; Kawai M; Maruko R; Sekiryu T; Okada AA; Iida T; Mori R
    Jpn J Ophthalmol; 2022 Jul; 66(4):379-385. PubMed ID: 35595951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
    Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
    Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of adverse events after loading phase of the brolucizumab therapy of neovascular AMD: Real-life evidence in the Czech Republic.
    Stepanov A; Studnicka J; Veith M; Nemec P; Vyslouzilova D; Koubek M; Nemcansky J
    Eur J Ophthalmol; 2022 Oct; ():11206721221132619. PubMed ID: 36254407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy.
    Fukuda Y; Sakurada Y; Matsubara M; Hasebe Y; Sugiyama A; Kikushima W; Kashiwagi K
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of Intravitreal Dexamethasone Implant Treatment for Diabetic Macular Edema in Vitrectomized Eyes.
    Özdemir HB; Hasanreisoğlu M; Yüksel M; Ertop M; Gürelik G; Özdek Ş
    Turk J Ophthalmol; 2019 Dec; 49(6):323-327. PubMed ID: 31893587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
    Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS
    Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Anti-VEGF Therapy on the Disease Progression of Neovascular Age-Related Macular Degeneration: A Systematic Review and Model-Based Meta-Analysis.
    Luu KT; Seal J; Green M; Winskill C; Attar M
    J Clin Pharmacol; 2022 May; 62(5):594-608. PubMed ID: 34783362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration-the FALCON study.
    Holz FG; Schmitz-Valckenberg S; Wolf A; Agostini H; Lorenz K; Pielen A; Feltgen N; Guthoff R; Quiering C; Clemens A; Jaeger K
    Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2695-2702. PubMed ID: 35188581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.